Trial Profile
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jul 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Filgrastim (Primary) ; Folinic acid (Primary) ; Mercaptopurine (Primary) ; Mesna (Primary) ; Methotrexate (Primary) ; Pegfilgrastim (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Tagraxofusp (Primary) ; Vincristine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 17 Feb 2022 Status changed from not yet recruiting to recruiting.
- 08 Sep 2021 New trial record